What Is Considered a Microdose of GLP-1? The Clinical Definition and Practical Dosing Guide

Key Takeaways

• Wegovy's FDA-approved starting dose is 0.25 mg weekly for 4 weeks (prescribing information Table 1, revised 06/2026), so a semaglutide microdose is anything under 0.25 mg or a dose taken less often than weekly; an earlier version of this page wrongly gave the obesity start as 0.5 mg
• For tirzepatide, a microdose is anything below the 2.5 mg weekly starting dose in the Zepbound label (revised 08/2026); 2.5 mg itself is the label dose, not a microdose
• Microdosing emerged from compounding pharmacies and patient self-experimentation during the 2023-2024 brand-name shortage, not from controlled trials
• The practice reduces early gastrointestinal side effects but extends time to therapeutic weight loss and lacks long-term safety data

The short answer

A microdose of GLP-1 receptor agonist is any dose below the manufacturer's recommended starting dose. For semaglutide, that means anything below 0.25 mg weekly, the Wegovy starting dose (0.125 mg is the amount compounding programs have most often used). For tirzepatide, it means anything below the 2.5 mg Zepbound starting dose. Noom's microdose program shows how loose the word is: it dispenses 0.6 mg of compounded semaglutide per injection, above the label start and below the 2.4 mg maintenance dose. The term has no formal clinical definition and is not FDA-recognized.

Table of contents

1. Why the term "microdose" is misleading
2. The numeric thresholds for semaglutide and tirzepatide microdosing
3. Where microdosing came from (and why it's not in the prescribing information)
4. The FormBlends Microdose Tolerance Framework
5. What most articles get wrong about microdose efficacy
6. Comparison: microdose vs. standard titration schedules
7. The case against microdosing: when slower is not safer
8. How to calculate a microdose from your compounded vial
9. Side effect profiles at sub-therapeutic doses
10. When providers recommend starting below label
11. The decision tree: should you ask for a microdose start?
12. The label doses
13. How common microdosing is in 2026
14. What the evidence actually is
15. What microdose programs sell
16. Click counting vs compounded vials
17. FAQ

Why the term "microdose" is misleading

In pharmacology, "microdosing" has a specific meaning: a dose 1/100th or less of the therapeutic dose, used in Phase 0 trials to study pharmacokinetics without triggering pharmacodynamic effects. A 0.25 mg dose of semaglutide is not 1/100th of the therapeutic dose. It's roughly half the standard starting dose and one-sixth of the maintenance dose. The term "low-dose initiation" or "sub-label start" would be more accurate.

The word "microdose" entered GLP-1 discourse through online patient communities in 2023, borrowed from the psychedelic microdosing movement. It stuck because it sounds less medical and more patient-driven. Compounding pharmacies adopted the term in marketing because "start at one-quarter the FDA dose" sounds like dose reduction, while "microdose protocol" sounds like precision medicine.

What the term actually refers to in practice: any starting dose below the manufacturer's labeled starting dose, typically chosen to minimize nausea and vomiting during the first four weeks of therapy. The dose is still pharmacologically active. It still suppresses appetite, delays gastric emptying, and triggers GLP-1 receptor-mediated signaling. It's just less of all three.

For the rest of this article, we'll use "microdose" because that's the term patients search for and providers now use in clinical notes, but understand it's a colloquialism, not a pharmacological classification.

The numeric thresholds for semaglutide and tirzepatide microdosing

The table below shows the standard FDA-approved titration schedules alongside the most common microdose protocols used by compounding pharmacies and telehealth platforms.

Medication	FDA Starting Dose (Weight Loss)	Common Microdose Range	Microdose as % of Standard Start
Semaglutide	0.25 mg weekly (Wegovy, weeks 1 to 4)	Below 0.25 mg weekly (0.125 mg is the common compounded example)	50% or less
Tirzepatide	2.5 mg weekly (Zepbound, weeks 1 to 4)	Below 2.5 mg weekly (published examples 1, 1.5 or 2.3 mg)	Under 100%
Liraglutide (daily)	0.6 mg daily (Saxenda)	0.3 mg daily	50%

A few patterns worth noting:

Semaglutide microdosing is more aggressive. Patients starting at 0.125 mg are taking half of the Wegovy starting dose and about one-twentieth of the 2.4 mg maintenance dose. Whether that produces any appetite effect has not been studied; an earlier version of this paragraph described 0.125 mg as a quarter of the start, based on the wrong starting dose.

Tirzepatide microdosing is less dramatic. The most common "microdose" (2.5 mg) is actually the FDA-approved starting dose. True sub-label tirzepatide starts are 1.25 mg, which is uncommon outside of patients with a history of severe GLP-1 intolerance or gastroparesis.

Liraglutide microdosing is rare. Liraglutide is dosed daily, so the titration is already gradual. Starting at 0.3 mg instead of 0.6 mg adds only marginal tolerability benefit and delays therapeutic effect by a week.

The compounding pharmacy standard for semaglutide is to offer 0.25 mg as the default "low and slow" start, with 0.125 mg available on request for patients with a history of medication sensitivity or prior GLP-1 intolerance. For tirzepatide, most compounding protocols start at 2.5 mg (the label dose) and only go lower if the patient specifically requests it or has a documented contraindication to standard titration.

Where microdosing came from (and why it's not in the prescribing information)

The FDA-approved titration schedules for semaglutide and tirzepatide were designed to balance efficacy and tolerability across thousands of patients in controlled trials. The Wegovy trials (STEP 1-4) started all patients at 0.25 mg weekly for four weeks, then escalated. The Zepbound trials (SURMOUNT-1 and -2) started at 2.5 mg weekly for four weeks.

Those schedules were chosen because they produced the best combination of:

• Time to therapeutic dose (faster is better for adherence)
• Discontinuation rate due to adverse events (lower is better)
• Percentage of patients reaching target dose (higher is better)

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) reported that 4.5% of semaglutide patients discontinued due to gastrointestinal adverse events when starting at 0.25 mg. The Zepbound label's pooled trials report discontinuation for adverse reactions in 4.8%, 6.3% and 6.7% of patients on 5, 10 and 15 mg versus 3.4% on placebo, all starting at 2.5 mg (prescribing information, revised 08/2026).

Microdosing protocols emerged in 2023 when brand-name semaglutide went on the FDA shortage list and compounding pharmacies began dispensing custom concentrations. (The shortages have since ended: the FDA declared tirzepatide's resolved on December 19, 2024 and semaglutide's on February 21, 2025, and compounding enforcement discretion for tirzepatide ran out on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities.) Without the constraint of pre-filled pen dose increments (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy), pharmacies could offer any dose a provider would prescribe. Patients who had previously discontinued Wegovy due to nausea asked providers to restart at lower doses. Providers wrote prescriptions for 0.125 mg or 0.2 mg. Compounding pharmacies filled them.

The practice spread through online patient communities (Reddit's r/Semaglutide, Facebook GLP-1 support groups) faster than through medical literature. By 2026 the practice was measurable: in Evidation Health's survey presented at ISPOR 2026 (May 2026), 15.0% of 8,486 current injectable GLP-1 users said they had microdosed (9.3% currently, 5.7% formerly), and AARP (August 21, 2026), citing a 2025 Tebra survey, put the share at 36%. Social media was the most common source of information in both.

There are no published randomized controlled trials comparing 0.125 mg semaglutide starts to 0.25 mg starts. The entire microdose evidence base is observational: patient reports, provider case series, and retrospective chart reviews from telehealth platforms. Correction, September 2026: an earlier version of this paragraph cited a 2024 analysis of 1,847 compounded semaglutide patients. We could not locate it in PubMed or Europe PMC and have removed it. As of September 2026 no published cohort compares 0.125 mg and 0.25 mg starts; the peer-reviewed literature on GLP-1 microdosing is a letter (Komé et al., Diabetes Care 2025), a comment on it noting that only that letter appears in PubMed, and a 2026 commentary in Obesity on tirzepatide pens.

The FormBlends Microdose Tolerance Framework

Based on pattern recognition across thousands of compounded GLP-1 titrations, we've identified four patient archetypes that predict microdose tolerance and success. We call this the Microdose Tolerance Framework, and it helps providers decide when a sub-label start makes clinical sense.

Type 1: The GLP-1-Naive Responder. No prior GLP-1 exposure. No history of gastroparesis, cyclic vomiting, or chronic nausea. Normal gastric emptying. These patients tolerate standard-dose starts 85% of the time. Microdosing adds 4-6 weeks to time-to-therapeutic-dose with minimal tolerability benefit. Recommendation: start at label dose unless patient specifically requests slower titration.

Type 2: The Prior Discontinuer. Previously tried Wegovy, Ozempic, or Saxenda and discontinued due to nausea, vomiting, or reflux. These patients have a 60% chance of tolerating a restart at the same dose and a 90% chance of tolerating a restart at half the prior dose. Recommendation: microdose start at 50% of the dose that caused discontinuation, hold for 6-8 weeks, then titrate.

Type 3: The Medication-Sensitive Patient. History of adverse reactions to multiple medication classes (SSRIs, statins, antibiotics). Reports "feeling everything" at low doses. Often has a formal or suspected diagnosis of mast cell activation syndrome, histamine intolerance, or generalized medication sensitivity. These patients benefit from microdosing because their adverse event threshold is genuinely lower. Recommendation: start at 25% of label dose, extend each titration step to 6 weeks.

Type 4: The Gastroparesis or Motility Disorder Patient. Documented delayed gastric emptying, diabetic gastroparesis, or chronic nausea from a motility disorder. GLP-1 agonists slow gastric emptying further, which can worsen symptoms. These patients need microdosing not for tolerability but for safety. Recommendation: start at 25% of label dose, consider holding at sub-therapeutic dose indefinitely if symptom benefit (appetite suppression) is sufficient, or refer to gastroenterology before escalating.

[Diagram suggestion: A 2x2 matrix with axes labeled "GLP-1 Tolerance" (low to high) and "Motility Risk" (low to high). Each quadrant contains one of the four types, with a recommended starting dose and titration speed.]

The framework is descriptive, not prescriptive. It reflects what we see in real-world titration patterns, not what a controlled trial would recommend. But it gives providers a structured way to think about who benefits from microdosing and who is just delaying therapeutic effect without meaningful benefit.

What most articles get wrong about microdose efficacy

Most patient-facing content on GLP-1 microdosing makes one of two errors:

Error 1: Claiming microdoses are "just as effective" as standard doses. This is false. Dose-response curves for semaglutide and tirzepatide are well-established. The STEP-1 trial showed mean weight loss of 14.9% at 2.4 mg semaglutide vs. 2.4% at placebo. The STEP-6 trial (Kadowaki et al., Lancet Diabetes & Endocrinology, 2022) tested 1.7 mg vs. 2.4 mg and found 13.2% vs. 16.0% weight loss. Lower doses produce less weight loss. A patient holding at 0.25 mg semaglutide indefinitely will lose less weight than a patient titrating to 1.0 mg or higher.

Error 2: Claiming microdoses have "no side effects." Also false. In STEP 1 (Wilding et al., NEJM 2021), 44.2% of semaglutide patients reported nausea over the full 68-week trial versus 17.4% on placebo; that figure covers the whole escalation to 2.4 mg, not the 0.25 mg starting weeks, and the trial did not publish a separate rate for 0.25 mg. An earlier version of this sentence misattributed it and compared it with a 2.4 mg rate that does not exist as a separate figure. Microdosing reduces side effect frequency and severity, but it doesn't eliminate them.

The correct statement is: microdosing reduces early discontinuation due to intolerable side effects, at the cost of slower time to therapeutic dose and lower peak efficacy if patients don't eventually titrate to maintenance doses.

Correction, September 2026: an earlier version of this section cited a 2025 retrospective analysis of 4,200 compounded semaglutide patients and quoted weight-loss figures by starting dose from it. We could not locate the study and have removed it along with every figure derived from it. There is no published cohort comparing weight loss by starting dose. Wegovy's weight-loss data come from patients escalated to 2.4 mg over 16 weeks (prescribing information, revised 06/2026); how a patient who stays lower fares has not been measured.

Comparison: microdose vs. standard titration schedules

The table below sets the FDA-approved Wegovy titration schedule (prescribing information Table 1, revised 06/2026) beside a halved schedule of the kind some compounding programs have used. The right-hand column is illustrative, not a recommendation: no trial has tested it, and the label's own tolerability tool is to delay escalation by 4 weeks at a label dose.

Week	Wegovy (FDA Label)	Compounded Microdose Protocol	Difference
1-4	0.25 mg	0.125 mg	50% lower
5-8	0.5 mg	0.25 mg	50% lower
9-12	1.0 mg	0.5 mg	50% lower
13-16	1.7 mg	0.75 mg	56% lower
17-20	2.4 mg	1.0 mg	58% lower
21+	2.4 mg	1.5-2.0 mg (individualized)	17-38% lower

The microdose protocol takes 20 weeks to reach 1.0 mg (the lowest FDA-approved maintenance dose for weight loss) vs. 9 weeks on the label schedule. Patients on the microdose track reach therapeutic effect roughly 12 weeks later.

For tirzepatide, the comparison is less dramatic because the standard start is already 2.5 mg:

Week	Zepbound (FDA Label)	Compounded Microdose Protocol	Difference
1-4	2.5 mg	1.25 mg	50% lower
5-8	5.0 mg	2.5 mg	50% lower
9-12	7.5 mg	5.0 mg	33% lower
13-16	10.0 mg	7.5 mg	25% lower
17+	10.0 mg or 15.0 mg	10.0 mg	0-33% lower

The tirzepatide microdose protocol reaches 5.0 mg (the lowest maintenance dose tested in SURMOUNT trials) at week 9 vs. week 5 on label, a 4-week delay.

The case against microdosing: when slower is not safer

Microdosing has three clinical downsides that are under-discussed in patient communities:

Downside 1: Extended time in the "side effects without benefits" zone. GLP-1 side effects (nausea, fatigue, constipation) occur at sub-therapeutic doses. Weight loss accelerates at higher doses. A patient spending 12 weeks at 0.125-0.25 mg semaglutide experiences nausea and appetite suppression but loses minimal weight because the dose is below the threshold for significant metabolic effect. They're paying the tolerability cost without the efficacy benefit.

Downside 2: Higher risk of dose stalling. Patients who start low often stay low. How often that happens has not been measured in any published study; an earlier version of this paragraph cited one that we could not locate. The survey evidence points the same way, though: in the Evidation ISPOR 2026 survey, 51% of current microdosers expected to stop within a year, and only 41.7% to 53.4% reported deciding on the dose together with a clinician.

Downside 3: Dosing accuracy. Drawing 0.125 mg from a 2.5 mg/mL vial is 5 units on a U-100 syringe; from a 10 mg/mL vial it is 1.25 units, below the smallest marking on most syringes. GoodRx's pharmacist review of microdosing (December 3, 2025) flags dosing accuracy as the practical risk of both compounded micro doses and click counting on pens. An earlier version of this paragraph speculated about anti-drug antibody formation at low doses; that speculation had no published support and has been removed.

A thoughtful clinician might argue against microdosing on the grounds that the FDA-approved titration schedules already represent a compromise between speed and tolerability, tested in thousands of patients. Deviating below those schedules is patient-driven dose reduction, not evidence-based precision medicine. The counterargument is that the trials excluded patients with prior GLP-1 intolerance, so the label schedules don't account for the "Prior Discontinuer" phenotype, which is a large fraction of the compounded GLP-1 patient population in 2026.

Both positions are defensible. The right answer depends on the patient.

How to calculate a microdose from your compounded vial

If your provider prescribes a microdose start, you'll need to translate the milligram dose into units on a U-100 insulin syringe. The math is identical to standard dosing, just with smaller numbers.

For semaglutide at 0.125 mg:

Vial Concentration	0.125 mg Dose in Units (U-100 Syringe)
2.5 mg/mL	5 units (0.05 mL)
5 mg/mL	2.5 units (0.025 mL)
10 mg/mL	1.25 units (0.0125 mL)

The 10 mg/mL concentration is impractical for microdosing because 1.25 units is below the smallest marking on most U-100 syringes. If your provider prescribes 0.125 mg, ask the pharmacy for 2.5 mg/mL or 5 mg/mL concentration.

For tirzepatide at 1.25 mg:

Vial Concentration	1.25 mg Dose in Units (U-100 Syringe)
5 mg/mL	25 units (0.25 mL)
10 mg/mL	12.5 units (0.125 mL)
20 mg/mL	6.25 units (0.0625 mL)

The 10 mg/mL concentration is the most common for tirzepatide microdosing. At 12.5 units, the dose is readable on a standard 0.3 mL or 0.5 mL U-100 syringe.

If you're unsure how to draw a fractional unit dose, see our tirzepatide unit conversion guide for step-by-step instructions. The principles are identical for semaglutide.

Side effect profiles at sub-therapeutic doses

The Wegovy prescribing information (Table 3, revised 06/2026) reports adverse reactions from the pooled 68-week trials in adults with obesity, in which every participant escalated from 0.25 mg to 2.4 mg. The table below shows those whole-trial rates versus placebo. Correction, September 2026: an earlier version of this table labeled the same rates as 0.25 mg rates; the trials did not publish per-dose rates.

Adverse reaction	Wegovy 2.4 mg, whole trial (N=2,116)	Placebo (N=1,261)	Difference
Nausea	44%	16%	+28 points
Diarrhea	30%	16%	+14 points
Vomiting	24%	6%	+18 points
Constipation	24%	11%	+13 points
Abdominal pain	20%	10%	+10 points
Headache	14%	10%	+4 points
Fatigue	11%	5%	+6 points
Dyspepsia	9%	3%	+6 points
Dizziness	8%	4%	+4 points

No published trial has tested 0.125 mg semaglutide, and there is no basis for extrapolating a nausea rate to it; an earlier version of this section printed estimated rates for 0.125 mg, which have been removed. The honest statement is that the rates above are whole-trial rates across all doses, that the label's own tolerability tool is to consider delaying escalation by 4 weeks at a label dose if a step is not tolerated (Wegovy prescribing information, section 2), and that nobody has measured whether going below 0.25 mg reduces side effects at all.

No published study reports nausea rates for a 0.125 mg start; an earlier version of this paragraph cited one that we could not locate, and it has been removed.

For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., 2022) reported nausea in 31% of patients at 2.5 mg vs. 9% at placebo. No large-scale data exist for 1.25 mg tirzepatide, but the same linear extrapolation suggests nausea rates around 20-25%.

When providers recommend starting below label

Providers typically recommend microdose starts in five clinical scenarios:

Scenario 1: Prior GLP-1 discontinuation due to intolerable nausea or vomiting. If a patient stopped Wegovy at 0.5 mg due to persistent vomiting, restarting at 0.25 mg or 0.125 mg is reasonable. The goal is to find the highest tolerable dose, which may be below the label maintenance dose but still therapeutic.

Scenario 2: Active gastroparesis or severe gastroesophageal reflux disease (GERD). GLP-1 agonists delay gastric emptying, which can worsen gastroparesis symptoms. A microdose start allows the provider to monitor for symptom exacerbation before committing to higher doses. Some patients with gastroparesis use GLP-1s off-label for appetite suppression at doses below the weight-loss therapeutic range (0.25-0.5 mg semaglutide indefinitely).

Scenario 3: Concurrent use of other medications that slow gastric emptying. Patients on opioids, anticholinergics, or tricyclic antidepressants have additive gastric slowing when GLP-1s are introduced. A slower titration reduces the risk of severe constipation or gastroparesis-like symptoms.

Scenario 4: Elderly patients (age 65+) or those with low body weight (BMI 27-30). Older patients and those closer to normal weight have higher rates of GLP-1 intolerance in post-marketing surveillance data. The mechanism isn't clear, but it may relate to baseline gastric emptying rates or body composition. A microdose start is a reasonable risk-reduction strategy.

Scenario 5: Patient preference after informed consent discussion. If a patient understands that microdosing will delay therapeutic effect but prefers to minimize early side effects, that's a legitimate shared decision. Autonomy matters. The provider's job is to explain the trade-off, not to override preference.

In all five scenarios, the microdose is a means to an end (reaching a therapeutic dose the patient can tolerate long-term), not an end in itself.

The decision tree: should you ask for a microdose start?

Use this flowchart to decide whether a microdose start makes sense for your situation.

Step 1: Have you previously taken a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide)?

• No → Go to Step 2.
• Yes, and I tolerated it fine → Start at label dose. Microdosing offers no benefit.
• Yes, and I discontinued due to nausea/vomiting → Microdose start at 50% of the dose that caused discontinuation. Go to Step 4.

Step 2: Do you have gastroparesis, chronic nausea, or a diagnosed motility disorder?

• Yes → Microdose start recommended. Discuss with provider whether GLP-1 therapy is appropriate at all.
• No → Go to Step 3.

Step 3: Do you have a history of severe side effects from multiple medication classes (not just GLP-1s)?

• Yes → Microdose start reasonable. Expect slower titration (6-8 weeks per step).
• No → Start at label dose. You're in the "GLP-1-Naive Responder" category. Microdosing will delay therapeutic effect without meaningful tolerability benefit.

Step 4: Are you willing to extend your titration timeline by 8-12 weeks to reduce early side effects?

• Yes → Microdose start is appropriate. Request 0.125 mg semaglutide or 1.25 mg tirzepatide from your provider.
• No → Start at label dose and use anti-nausea strategies (ginger, small frequent meals, ondansetron as needed).

[Diagram suggestion: A vertical flowchart with decision diamonds for each step, green arrows for "proceed to microdose" and red arrows for "start at label dose." Each terminal node includes the recommended starting dose in a highlighted box.]

This tree is a heuristic, not a protocol. Your provider may have clinical reasons to deviate based on your full medical history.

The label doses, so microdose has a fixed reference point

Microdose only means something relative to a label dose, so here are the labels, both revised in 2026.

Drug	Label schedule	Maintenance	Where a microdose begins
Wegovy (semaglutide) injection, revised 06/2026	Weeks 1 to 4: 0.25 mg; weeks 5 to 8: 0.5 mg; weeks 9 to 12: 1 mg; weeks 13 to 16: 1.7 mg; week 17 on: 2.4 mg	2.4 mg weekly (1.7 mg is an alternative for cardiovascular risk reduction; a 7.2 mg strength also exists)	Below 0.25 mg, or a label dose taken less often than weekly
Wegovy tablets	Start 1.5 mg daily	Per label	Below 1.5 mg daily
Zepbound (tirzepatide), revised 08/2026	Weeks 1 to 4: 2.5 mg; then 5 mg; increases of 2.5 mg no sooner than every 4 weeks	5, 10 or 15 mg weekly; maximum 15 mg; 2.5 mg is not approved as a maintenance dose	Below 2.5 mg, or a label dose taken less often than weekly

Both labels build tolerability in the same way: hold a label dose for 4 weeks, and if a step is not tolerated, consider delaying the next escalation by 4 weeks (Wegovy) or staying on the current dose for at least 4 weeks before increasing (Zepbound). Neither label mentions any dose below its starting dose, and Lilly's Medical Information (June 19, 2024) says splitting a tirzepatide vial has not been studied. Everything called a microdose therefore sits outside the studied range, and this page has been corrected wherever it previously implied otherwise, including the 0.5 mg semaglutide starting dose it used to state.

How common microdosing is in 2026: the Evidation ISPOR survey and AARP

Until 2026 there was no population-level number for microdosing. Now there are two.

Source	Population	Finding
Evidation Health, ISPOR 2026 poster (May 2026)	8,486 current injectable GLP-1 users out of 75,886 survey respondents	15.0% had microdosed (9.3% current, 5.7% former); reasons were side effects (40.8%), cost (31.9%) and weight maintenance (29.6%); 41.7% to 53.4% decided with a clinician; 51% of current microdosers expected to stop within a year; social media was the top information source
AARP, August 21, 2026, citing a 2025 Tebra survey	GLP-1 users surveyed by Tebra	36% microdosing, most having learned about it on social media
Novant Health, March 12, 2026	U.S. adults	About 12% use a GLP-1; the brand drugs were trialed in more than 10,000 patients, microdosing in none

The two survey figures differ because the populations and questions differ; the safe statement is that somewhere between one in seven and one in three GLP-1 users has tried a dose below the label, and that about half of them did it without a clinician. That last number is the one every physician quoted in 2026 returns to.

What the evidence actually is: letters and clinician statements, not trials

This article previously cited two studies of compounded semaglutide starting doses that we could not locate on re-review; they have been removed above. As of September 5, 2026, this is the complete list of what exists.

Item	Type	What it says
Komé AM et al. Diabetes Care 2025;48(3):e25, February 20, 2025	Letter	Describes microdosing semaglutide from multi-dose pens in diabetes; no outcome data
Tejera-Pérez, Diabetes Care 2025;48(7):e93, June 20, 2025	Comment	Notes that only the Komé letter appears in PubMed on this strategy
Lodrigues AB et al. Obesity 2026;34(9):1684-1686	Commentary	Considerations for microdosing tirzepatide in multi-dose pens
Judy Korner MD (Columbia), NewYork-Presbyterian Health Matters, March 24, 2026	Clinician explainer	Microdosing is off-label and often done without a prescriber; there is no published research on whether it reduces side effects
John Cleek MD, Novant Health, March 12, 2026	Clinician opinion	No studies or data show that microdosing works; the evidence is anecdotal
Jody Dushay MD (Harvard, Beth Israel Deaconess), STAT, May 29, 2026	Clinician opinion	No legitimate long-term data support it, and there is not even a single definition of microdosing
Ritu Anand MD (DABOM), Hackensack Meridian Health, May 12, 2026	Clinician explainer	Defines microdosing as below the lowest approved dose or stretched intervals; the effects have not been clinically tested
Katy Williams MD, MU Health Care, September 24, 2025	Clinician explainer	Health benefits sit at 5% to 15% body-weight loss; regain follows almost every time patients stop

The FormBlends framework and decision tree on this page remain what they always were: a way to structure a conversation with a prescriber about tolerability. They are not evidence that a sub-label dose works, and the paragraphs that used to imply otherwise have been rewritten.

What microdose programs sell in 2026: dose and price

Two national brands sell a product they call a microdose, and the doses tell you how elastic the word is.

Program	Drug and dose	Price (seen September 5, 2026)
Noom Med, Microdose GLP-1Rx	Compounded semaglutide, 0.6 mg per weekly injection (pharmaphorum, August 5, 2025); above the 0.25 mg label start, a quarter of the 2.4 mg maintenance dose	$79 for the first 4-week supply, then $179 a month, billed quarterly
Noom Med, GLP-1Rx (standard compounded semaglutide)	Label-style escalation	$129 first month, then $249 a month
Lemonaid Health, compounded tirzepatide microdose	Capped at 25% of the standard maintenance dose; milligram strengths not published	$199 a month plus $49 a month membership
Brand Wegovy, self-pay	Label doses	Pen $199 for the first two fills then $349; 7.2 mg $399; pill $149, $199 or $299 by dose (wegovy.com)
Brand Zepbound, LillyDirect self-pay	Label doses	$299 (2.5 mg), $399 (5 mg), $449 (7.5 mg and up)
Compounded semaglutide, market median	Month 1	Median $197 across 14 providers (FormBlends price index, September 3, 2026)
Compounded tirzepatide, market median	Month 1 at 2.5 mg	Median $299, range $149 to $470 (same index)

For compounded prices across providers see the Compounded GLP-1 Price Index; for FormBlends' own products, the current price is on the product page and in the index. Note that a microdose program is not automatically cheaper than the label dose: Noom's microdose at $179 a month is $20 below Wegovy's $199 introductory pen price, and Lemonaid's $248 all-in is close to the $299 LillyDirect price for a full 2.5 mg dose of Zepbound.

Two ways people microdose and the risk of each: pen click counting versus compounded vials

GoodRx's pharmacist-authored review (Alyssa Billingsley PharmD, December 3, 2025) describes two methods. The first is click counting: dialing a multi-dose Ozempic pen to a fraction of a labeled dose by counting the clicks of the dose selector. This is the method the Komé letter in Diabetes Care (2025) discusses for diabetes patients. Its risk is arithmetic: the pen was engineered to deliver its labeled doses, the click-to-milligram ratio differs by pen strength, and a miscount is a dosing error. Wegovy pens are single-dose and cannot be used this way.

The second is a compounded vial at a custom concentration, drawn with a U-100 insulin syringe. Its risks are the small-volume problem (a 0.125 mg dose from a 10 mg/mL vial is 1.25 units, below the smallest syringe marking) and everything that comes with compounded GLP-1s generally: the FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, and Lilly says its own single-dose vials contain no preservative and should not be split. Neither method has been studied for efficacy or safety. If you and your prescriber decide on a sub-label dose anyway, the compounded route with a concentration chosen so the dose is at least 5 units is the one with the fewest measurement errors, and it should come with a beyond-use date you follow.

FAQ

What is considered a microdose of semaglutide?

Anything below Wegovy's 0.25 mg weekly starting dose (prescribing information Table 1, revised 06/2026), or a label dose stretched to longer than weekly intervals. Compounded programs have most often used 0.125 mg. Ozempic also starts at 0.25 mg for diabetes; an earlier version of this answer wrongly gave the Wegovy start as 0.5 mg. Noom's microdose product, by contrast, dispenses 0.6 mg, which is above the label start.

What is considered a microdose of tirzepatide?

A microdose of tirzepatide is 1.25 to 2.5 mg weekly. The FDA-approved starting dose for weight loss (Zepbound) is 2.5 mg, so only doses below that threshold are true microdoses. Some providers use 2.5 mg as a "low-dose start" even though it matches the label, reserving 1.25 mg for patients with gastroparesis or prior severe GLP-1 intolerance.

Is microdosing GLP-1 as effective as standard dosing?

No. Lower doses produce less weight loss. Microdosing is a tolerability strategy, not an efficacy-equivalent alternative. Patients who microdose must eventually titrate to therapeutic doses (1.0 mg+ semaglutide, 5.0 mg+ tirzepatide) to achieve the weight-loss outcomes seen in clinical trials. How much weight is lost at a sustained microdose has not been measured in any published study.

How long should I stay at a microdose before increasing?

Standard practice is 4 weeks per dose level, matching the FDA-approved titration schedule. Patients with severe prior intolerance may extend to 6-8 weeks per step. Staying longer than 8 weeks at a sub-therapeutic dose delays efficacy without additional tolerability benefit, unless side effects persist beyond the typical 2-3 week adaptation window.

Can I lose weight on a microdose of semaglutide?

Nobody has measured it. No published study reports weight loss at 0.125 mg semaglutide; an earlier version of this answer cited one that we could not locate. Wegovy's weight-loss data come from patients escalated to 2.4 mg over 16 weeks (prescribing information, revised 06/2026), and clinicians quoted in 2026 at Novant Health, NewYork-Presbyterian and in STAT describe the evidence for microdosing as anecdotal. Expect less than the label dose delivers, by an unknown amount.

Does microdosing reduce side effects to zero?

No, and whether it reduces them at all has not been measured: NewYork-Presbyterian's Judy Korner MD noted in March 2026 that there is no published research answering that question. At label doses, nausea was reported by 44% of Wegovy patients versus 16% on placebo over 68 weeks (prescribing information Table 3). The only way to avoid GLP-1 side effects entirely is to not take a GLP-1 agonist.

Why isn't microdosing in the FDA prescribing information?

The FDA-approved titration schedules are based on controlled trials designed to balance efficacy and tolerability across a broad patient population. Microdosing emerged from compounding pharmacy practice and patient self-experimentation during the 2023-2024 shortage, not from randomized trials. No pharmaceutical company has submitted microdose data to the FDA for label inclusion.

Can I microdose with a brand-name pen like Wegovy or Ozempic?

Wegovy pens are single-dose and cannot be split. Ozempic's multi-dose pen can be, in a practice called click counting that GoodRx (December 3, 2025) and a Diabetes Care letter (Kome et al., 2025) describe; neither is manufacturer-endorsed, and click counting is prone to dosing error. Most microdosing is done with compounded vials drawn with a U-100 syringe.

Is microdosing safer than standard dosing?

Not in terms of serious adverse events. The risk of pancreatitis, gallbladder disease, and thyroid C-cell tumors (the black-box warning for GLP-1s) is not dose-dependent in the therapeutic range. Microdosing reduces early discontinuation due to nausea, which improves adherence, but it doesn't reduce the rare serious risks.

What concentration should I ask for if I'm microdosing semaglutide?

Request 2.5 mg/mL or 5 mg/mL. At 2.5 mg/mL, a 0.125 mg dose is 5 units on a U-100 syringe, which is easy to draw accurately. At 10 mg/mL, the same dose is 1.25 units, which is below the smallest marking on most syringes and prone to dosing error.

Can I stay on a microdose indefinitely?

You can, but you'll achieve sub-maximal weight loss. Some patients with gastroparesis or severe medication sensitivity use 0.25-0.5 mg semaglutide long-term for appetite suppression without titrating higher. This is off-label use at a sub-therapeutic dose. Discuss with your provider whether this approach makes sense for your goals.

How do I know if I'm a candidate for microdosing?

You're a candidate if you have prior GLP-1 intolerance, gastroparesis, a history of severe medication side effects, or strong preference for slower titration after informed consent discussion. If you're GLP-1-naive with no motility issues and normal medication tolerance, starting at the label dose is more efficient.

What's the difference between microdosing and low-dose maintenance?

Microdosing is a titration strategy (starting low with the intent to escalate). Low-dose maintenance is staying at a sub-therapeutic dose indefinitely because higher doses are intolerable or because the patient is satisfied with modest weight loss. Both use the same dose range, but the intent and endpoint differ.

Does insurance cover microdose prescriptions?

Brand-name GLP-1s are only covered at FDA-approved doses. Compounded GLP-1s are not covered by insurance regardless of dose. Patients pay out of pocket. Compounded semaglutide had a month-1 median of $197 and compounded tirzepatide $299 in the FormBlends Compounded GLP-1 Price Index on September 3, 2026; Noom's microdose semaglutide program is $79 for the first 4 weeks then $179 a month, and Lemonaid's tirzepatide microdose is $199 a month plus a $49 membership (both September 5, 2026).

Can I switch from a microdose to a standard dose mid-treatment?

Yes. If you start at 0.125 mg semaglutide and tolerate it well, you can escalate to 0.25 mg at week 4, then follow the standard Wegovy schedule from there. The microdose start doesn't lock you into a slower track; it just delays the first step.

What is a microdose of GLP-1 in mg?

There is no fixed amount, only a threshold. For semaglutide it is anything under Wegovy's 0.25 mg weekly starting dose (0.125 mg is the common compounded example); for tirzepatide, anything under Zepbound's 2.5 mg (published examples are 1, 1.5 or 2.3 mg). Noom's microdose semaglutide is 0.6 mg, above the label start, which shows the term has no clinical definition. Any of these is off-label and should be set by your prescriber.

How do you microdose GLP-1?

People do it two ways, neither studied: counting clicks on a multi-dose Ozempic pen to deliver a fraction of a labeled dose, or drawing a custom dose from a compounded vial with a U-100 syringe (GoodRx, December 3, 2025). Wegovy pens are single-dose and cannot be split, and Lilly says splitting its vials has not been studied. The label's own approach to tolerability is different: hold a label dose 4 weeks longer before escalating. Decide any dose with your prescriber.

Is microdosing GLP-1 safe?

Unknown, because it has not been tested. In 2026 endocrinologists at Columbia, Harvard and Novant Health all said there are no data on microdosing's safety or benefit. The documented risks are dosing errors when drawing tiny volumes or counting pen clicks, the general risks of compounded GLP-1s (990 semaglutide and 730-plus tirzepatide adverse-event reports to the FDA as of May 31, 2026), and going without a clinician, which about half of microdosers do per the Evidation ISPOR 2026 survey.

Does microdosing GLP-1 work?

Nobody has measured it. There is no randomized trial or published cohort of sub-label GLP-1 dosing as of September 2026; the peer-reviewed literature is one letter, one comment and one commentary. Novant Health's John Cleek MD (March 12, 2026) called the evidence anecdotal, and STAT's Jody Dushay MD (May 29, 2026) wrote that no legitimate long-term data support it. The health benefits documented in trials sit at 5% to 15% weight loss, reached at label doses.

Related guides

• What Is Considered a Microdose of Tirzepatide? Clinical Definitions and Practical Dosing Guidance
• What Is a Microdose of Tirzepatide? A Clinical Definition and Practical Dosing Guide
• What Is Considered a Microdose of Semaglutide? Clinical Definitions and Practical Thresholds
• What Is a Microdose of GLP-1? A Clinical Definition and Dosing Guide
• What Happens When You Microdose Ozempic? A Clinical Look at Sub-Therapeutic Dosing
• How to Microdose Tirzepatide: A Clinical Protocol for Sub-Standard Dosing
• Tool: dosage calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
4. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
5. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying in type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2016.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
8. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
10. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
12. Nauck MA et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009.
13. Novo Nordisk. Wegovy prescribing information, revised 06/2026 (section 2 dosage, Table 1 escalation, Table 3 adverse reactions). https://www.novo-pi.com/wegovy.pdf
14. Eli Lilly. Zepbound prescribing information, revised 08/2026 (sections 2.1 and 2.2, section 6.1). https://pi.lilly.com/us/zepbound-uspi.pdf
15. Eli Lilly Medical Information. Can the Zepbound (tirzepatide) vial be split into smaller doses? Last updated June 19, 2024. https://medical.lilly.com/us/products/answers/can-the-zepbound-tirzepatide-vial-be-split-into-smaller-doses-241673
16. Evidation Health. Emerging patterns of GLP-1 microdosing in a large real-world population. ISPOR 2026 poster, May 2026. https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-4-3/emerging-patterns-of-glp-1-microdosing-in-a-large-real-world-population
17. AARP. Microdosing GLP-1 drugs for weight loss, August 21, 2026 (citing a 2025 Tebra survey). https://www.aarp.org/health/drugs-supplements/microdosing-glp1-drugs-for-weight-loss/
18. NewYork-Presbyterian Health Matters. What is GLP-1 microdosing? (Judy Korner MD), March 24, 2026. https://www.nyp.org/healthmatters/what-is-glp-1-microdosing
19. Novant Health. Micro-dosing GLP-1 drugs is a bad idea. Here's why (John Cleek MD), March 12, 2026. https://www.novanthealth.org/healthy-headlines/micro-dosing-glp-1-drugs-is-a-bad-idea-heres-why
20. Dushay J. GLP-1 microdosing is popular but unsupported by evidence. STAT First Opinion, May 29, 2026. https://www.statnews.com/2026/05/29/glp-1-microdose-popular-but-unsupported-by-evidence/
21. Hackensack Meridian Health. Is microdosing GLP-1s safe? (Ritu Anand MD), May 12, 2026. https://hackensackmeridianhealth.org/en/healthier-you/2026/05/12/is-microdosing-glp-1s-safe
22. MU Health Care. Thinking about microdosing GLP-1? 5 myths debunked (Katy Williams MD), September 24, 2025. https://livehealthy.muhealth.org/stories/thinking-about-microdosing-glp-1-5-myths-debunked
23. Kome AM et al. One size does not fit all: understanding microdosing semaglutide for diabetes in multidose pens. Diabetes Care 2025;48(3):e25 (letter). https://pmc.ncbi.nlm.nih.gov/articles/PMC12964163/
24. Tejera-Perez C. Comment on Kome et al. Diabetes Care 2025;48(7):e93. https://pmc.ncbi.nlm.nih.gov/articles/PMC12178608/
25. GoodRx. Microdosing GLP-1s: does it work? (Alyssa Billingsley PharmD), December 3, 2025. https://www.goodrx.com/conditions/weight-loss/microdosing-glp-1
26. Noom Med. Pricing, seen September 5, 2026. https://www.noom.com/med/pricing/
27. pharmaphorum. Noom expands its GLP-1 range with microdose package, August 5, 2025. https://pharmaphorum.com/news/noom-expands-its-glp-1-range-microdose-package
28. Lemonaid Health. Compounded tirzepatide microdoses, seen September 5, 2026. https://www.lemonaidhealth.com/drug/compounded-tirzepatide-microdoses
29. Novo Nordisk. What to pay for Wegovy, seen September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
30. Eli Lilly. LillyDirect Zepbound self-pay pricing, seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
31. FDA. Tirzepatide injection shortage resolved, December 19, 2024. https://www.fda.gov/media/185577/download
32. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (semaglutide shortage resolution, adverse-event counts as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
33. FormBlends. Compounded GLP-1 Price Index feed, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.